- EXOGENIS For Clinics & Partners
Add a new treatment step to your clinic
ExoGenis integrates into existing treatments to enable repeatable biologic delivery — post-procedure and between visits. Simple to implement, easy to scale.
Integrated
Works seamlessly with existing treatments and clinical workflow.
Repeatable
Enables delivery between visits for better, longer-lasting results.
Profitable
A structured protocol that supports clinic growth.
ExoGenis maintenance protocol
A structured approach for optimal results and patient continuity, designed for use in clinical workflows.
01. IN CLINIC
Post-procedure application
- Apply ExoGenis post-procedure
- Enhance treatment outcomes
- Start the biologic delivery
02. AT HOME
.webp)
Between visits
- Patient applies patch at home
- Supports ongoing delivery
- Maintains results
03. FOLLOW UP
.webp)
Next visit
- Assess and continue protocol
- Build on previous results
- Drives patient loyalty
Example clinic revenue potential
.svg)
100
patients / month
.svg)
.svg)
30 %
use the protocol → 30 patients
.svg)
€100–150
per protocol
Potential additional revenue
€3,000 – €4,500 / month
Illustrative example. Actual results may vary.
Not just a product - a structured, repeatable treatment protocol clinics can sell, scale, and reorder.
- Why Partner With Us
Partnership value proposition
ExoGenis partners with a limited number of aesthetic and dermatology clinics to validate a new delivery layer, designed to support existing injectable and device-based treatments where injections are not optimal.
Clinical Differentiation
Ready-to-deploy protocols with training and implementation support.
Operational Efficiency
Increase patient throughput without increasing procedure time.
Protocol Integration
Structured training and implementation support.
Early Access & Co-development
Early access to a new treatment category with performance data participation.
- 2026 Co-Creation Partnership
The future of injection-free biologics
We are selecting 3–5 elite clinics to co-develop high-efficacy protocols. Bridge the gap between breakthrough technology and clinical excellence.
Month 0
01
Partner onboarding
Month 1
02
Protocol integration
Month 2
03
Controlled pilot deployment
Month 3
04
Performance review & scale decision
Willingness to participate in structured data collection and feedback during pilot phase
- protocol
ExoGenis maintenance protocol
Designed for clinic deployment and structured pilot testing.
When it’s used
- Post-procedure (laser, RF, injectables)
- Between treatment sessions
- Ongoing maintenance programs
How it’s sold
- 4–12 treatment programs
- Add-on or standalone
- Continuation of clinical results
Why it works commercially
- Designed for recurring usage per patient
- No additional chair time
- Fits existing workflows
- 4–12 applications per treatment cycle
- 2026 Launch
Is your clinic a good fit?
We're looking for forward-thinking clinics that share our commitment to innovation and patient care excellence.
- Perform injectable or device-based treatments
- Work with biologic actives (exosomes, peptides, growth factors)
- Want structured maintenance protocols
- Value clinical differentiation
Adds a new revenue-generating treatment layer
Integrates seamlessly into existing clinic workflows
Extends the clinical toolkit without replacing injectables or devices.
Extends and enhances treatment outcomes between visits
Supports maintenance, recovery, and biologic support between major procedures.
Fits real clinical workflows
Non-injectable, low-burden, and suitable for repeat or adjunct use.
High-margin recurring revenue stream
Revenue depends on protocol design, pricing, and patient adoption - validated during pilot phase.
- LIMITED EARLY ACCESS
Partnership application
ExoGenis is currently onboarding a limited number of clinics and strategic partners for early collaboration, validation dialogue, and future commercial access.
We are especially interested in dermatology, regenerative aesthetics, and biologic-focused clinical workflows.
*Developed in collaboration with clinical, academic, and biologic delivery partners including DTU and international validation collaborators.